Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00928811 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Safety of Chronic Administration of Simulect to Subjects Receiving a First Kidney Transplant
A Phase 2 study, sponsored by Drexel University College of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT00928811: Clinical Trial Phase 2 study, sponsored by Drexel University College of Medicine.
NCT00928811 is a Phase 2 study that was terminated before completion, run by Drexel University College of Medicine. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00928811, a Phase 2 study, was terminated before completion, sponsored by Drexel University College of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The study is undertaken to explore the safety of using Simulect at monthly dose intervals to reduce the need of high dose/level CNI's such as Prograf.
Interventions
- DRUG basiliximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2009-05 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Why NCT00928811 stopped before completion
NCT00928811 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which basiliximab is the first listed.
NCT00928811 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00928811 about?
NCT00928811 is a clinical study titled "Study to Evaluate the Safety of Chronic Administration of Simulect to Subjects Receiving a First Kidney Transplant". The study is undertaken to explore the safety of using Simulect at monthly dose intervals to reduce the need of high dose/level CNI's such as Prograf.
What is the current status of trial NCT00928811?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2009-05. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00928811?
The interventions under investigation include: basiliximab (DRUG).
Who is sponsoring clinical trial NCT00928811?
This trial is sponsored by Drexel University College of Medicine, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00928811's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia